MedPath

Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous

Phase 2
Conditions
Chronic Kidney Disease stage3
Interventions
Drug: Activated charcoal
Dietary Supplement: Dry seeds
Registration Number
NCT04311645
Lead Sponsor
Assiut University
Brief Summary

The study aims to explore the ability of Oral activated charcoal to adsorb uremic toxins limiting the progression of chronic kidney disease and delaying the need for hemodialysis in patients with CKD stages III and IV.

To compare its effect with the effect of dry seeds as absorbents of uremic toxins

Detailed Description

In recent years, chronic kidney disease(CKD) has become a worldwide public health issue.

The main factors affecting the prognosis of patients with chronic kidney disease are its complications, including cardiovascular and cerebrovascular diseases, malnutrition, inflammation, atherosclerosis syndrome, and anemia.

The accumulation of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, is implicated in the progression of renal failure and cardiovascular disease.

For many patients, chronic kidney disease (CKD) is a progressive condition marked by deteriorating renal function ultimately leading to end-stage renal disease (ESRD) and many patients refuse to start chronic hemodialysis.

Therapeutic approaches that decrease the level of uremic toxins are a rational method for inhibiting this progression.

Many researches have been done aiming to find alternatives for chronic hemodialysis either for economic issues or psychological issues especially in elderly patients, as example:

* Gum Arabic in the remedy and amelioration of kidney dysfunction and end-stage renal disease

* skin as excretory root for urea, increasing sweat from sweat glands can support kidney function by excreting a good amount of what kidneys naturally excrete.

* The oral charcoal adsorbent reduces serum levels of indoxyl sulfate through adsorption of indole converted from dietary tryptophan in the gastrointestinal tract decreasing serum creatinine and urea level .

In this study, the clinical data supporting the role of oral activated charcoal in a dose of 30gm/ day for slowing the progression of CKD will be reviewed.

In this study, a trial will be done using dry seeds (lentils as an example) as an absorbent for uremic toxins comparing its effect with the effect of oral activated charcoal.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria

Patients with CKD stages iii and iv

Patients with age more than 18 years old

Read More
Exclusion Criteria

Patients on regular hemodialysis

Patients with age less than 18 years old

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1st groupActivated charcoalOral activated charcoal in a dose of 30 gm/day
2nd groupDry seedsDry seeds in a dose of 1 gm/ day
Primary Outcome Measures
NameTimeMethod
Mean of blood urea, creatinine and phosphorous in patients with CKD before and after oral activated charcoalbaseline

to asses the mean of blood urea, creatinine and phosphorous in CKD patient before and after administration of activated charcoal

Secondary Outcome Measures
NameTimeMethod
comparison of dry seeds and activated charcoal in limitting progression of chronic kidney diseasebaseline

To compare dry seeds with activated charcoal as as alternative natural cheap methods that may help in limitting progression of CKD by measuring blood urea, creatinine, and phosphorous in all 3 groups of the study

© Copyright 2025. All Rights Reserved by MedPath